Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/08—Tripeptides
  • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q2337/00—N-linked chromogens for determinations of peptidases and proteinases
  • C12Q2337/10—Anilides
  • C12Q2337/12—Para-Nitroanilides p-NA
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/90—Enzymes; Proenzymes
  • G01N2333/914—Hydrolases (3)
  • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
  • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
  • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
  • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
  • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
  • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
  • G01N2333/96433—Serine endopeptidases (3.4.21)
  • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
  • G01N2333/96461—Protein C (3.4.21.69)
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates, as new industrial products, to the peptide substrates of formula I below and their addition salts.
• HD-Lys (Cbo) -L-Pro-L-Arg-pNA (Ilb) has already been used in the field of the determination of Protein C but that its effectiveness is lower than that of the abovementioned compound lia.
• Protein C which is commercially available.
• peptide substrates are characterized as new industrial products, characterized in that they are chosen from the group consisting of
• Y represents H or an appropriate group blocking the N-terminal end
• a 1 represents an amino acid residue chosen from the group consisting of (2-oxo-thiazolidin-4-yl) carbonyl residues [in ge. Abbreviation: THC], (2-oxo-tetrahydro-1,3-thiazin-
• a £ represents an amino acid residue chosen from the group consisting of the Pro, 3Hyp and 4Hyp residues, where the lateral OH group of 3Hyp and 4Hyp is capable of being protected by an ether or ester protecting group
• a 3 represents an amino acid residue chosen from the group consisting of the Arg and Lys residues
• R represents a labeling means
• the use of the tripeptide compounds of formula I and their addition salts is recommended for the determination of Protein C.
• a determination method is recommended for the determination or l identification of Protein C comprising bringing a tripeptide of formula I or one of its addition salts into contact with a body fluid (notably plasma or blood serum, or even urine) or any other natural or synthetic sample that may contain Protein C.
• ATC thiazolidine-4-carbonyl (or thioprolyl)
• AZC (tetrahydro-1,3-thiazin-5-yl) carbonyl
• 3Hyp 3-hydroxyprolyle (or 3-hydroxy-2-pyrrolidinecarbonyl
• THC (2-oxo-thiazolidin-4-yl) carbonyl
• TZC 2-oxo-tetrahydro-1,3-thiazin-5-yl) carbonyl
• DCCI dicyclohexylcarbodiimide
• H-TFA trifluoroacetic acid (or alternatively
• Ph phenyl
• PH cologarithm of the concentration of H + ions
• amino acid residue A 1 can be represented by the following structural formula
• B represents a single bond or the CH 2 group
• X represents CH 2 or CO.
• the pair (B; X) represents (-; CO), (CH 2 ; CO), (-; CH 2 ) and respectively (CH 2 ; CH 2 ),
• a 1 represents THC, TZC, ATC and AZC respectively.
• the amino acid residue A 1 will be, according to the invention, of configuration D or L or else a racemic mixture (DL) of these two configurations.
• a 1 will represent D-THC, D-TZC, D-ATC, D-AZC and better still L-THC, L-TZC, L-ATC and L-AZC.
• the amino acid residue A 1 which is considered to be the most advantageous according to the invention is L-THC.
• C 1 -C 4 alkyl groups in particular Me, Et, Pr, iPr, Bu, tBu
• optionally substituted aryl in particular Ph, tolyl, xylyl, chlorophenyl, trifluoromethylphenyl, methoxyphenyl
• optionally substituted aralkyl in particular Bzl, chlorobenzyl, dichlorobenzyl, trifluoromethylbenzyl, difluorobenzyl, methoxy-benzenzyl methylenedioxybenzyle
• the classic protecting groups of the N-terminal end of peptides in particular Ac, Tos, Adoc, Aoc, Bz, Cbo, Fmoc, Foc, Iboc, Z, Z (p-Cl) and Z (p-OMe )].
• scheme A or B will depend on (i) the nature of the blocking group, and (ii) the labile nature of the hydrogen atom of the N-terminal end which is in position 3 of the ring of A 1 .
• a 1 is THC or TZC, we will rather use scheme A.
• the preferred group Y according to the invention is H.
• the lateral OH group of 3Hyp and 4Hyp can be protected in ether or ester form.
• the protective group replacing the atom H of said OH group may in particular be a C 1 -C 4 alkyl group (in particular Me, Et, Pr, iPr, Bu, tBu), optionally substituted aryl (especially Ph, tolyl, xylyl, chlorophenyl , trifluoromethylphenyl, methoxyphenyl), optionally substituted aralkyl (in particular Bzl, chlorobenzyl, difluorobenzyl, trifluoromethylbenzyl, dichlorobenzyl, methoxybenzyl, ethoxybenzyl, 3,4-methylenedioxybenzyl) as envisaged in the defintion in the defintion in the defintion protection in the defintion in the defintion ether form; or by a C 2 -C 5 aliphatic acyl group (in particular
• amino acid residues A 2 and A 3 will be of configuration L, and the preferred groups for A 2 and respectively A 3 according to the invention will be L-Pro, L-3Hyp and L-4Hyp, and respectively L-Arg and L- Lys.
• the marking means R is well known in the technique of biological and microbiological assays, see for this purpose the abovementioned prior art and in particular document US-A-4,448,715.
• Said marking means will be preferably chosen from the group of amino groups NH-R 'which (i) induce a modification of coloration, (ii) induce a modification of fluorescence or (iii) contain at least one radioactive element (for example a labeled anilino or benzylamino group by a radiosotope 1 4 C or 3 H).
• any amino group NH-R 'giving during or after the enzymatic reaction a signal capable of being amplified to be detected for example by measuring the optical density under a given wavelength, or alternatively by measurement of radioactivity.
• the quantity of HR product obtained by cleavage during the enzymatic hydrolysis is proportional to the quantity of enzyme used. Said amount of HR can be determined photometrically, spectrophotometrically, fluorospectrophotometrically or electrochemically.
• the group R which is preferred according to the invention is a chromogenic group, typically a nitrophenyl group (in which the phenyl residue is capable of being substituted by a COOH, F, Cl, Br, CH 3 , OCH group. 3 , CN, CF 3 , and / or SO 3 H), or a fluorogenic group, typically a naphthyl group (in which the naphthyl residue is capable of being substituted by an OCH 3 , COOH, SO 3 H group or CH 3 ), and the groups 4-methylcoumaryl-7-amino, 4-trifluoromethylcoumaryl-7-amino and the like.
• a chromogenic group typically a nitrophenyl group (in which the phenyl residue is capable of being substituted by a COOH, F, Cl, Br, CH 3 , OCH group. 3 , CN, CF 3 , and / or SO 3 H)
• a fluorogenic group typically a naphth
• chromogenic and fluorogenic amino groups which are suitable according to the invention, include p-nitroanilino (abbreviated as pNA), 2-carboxy-4-nitroanilino and 3-carboxy-4-nitroanilino, 2-halo-4-nitroanilino and 3-halo-4-nitroanilino (where halogen is F, Cl or Br), 2-methoxy-5-methyl-4-nitroanilino, 2-hydroxysulfonyl-4-nitroanilino, 4-tri-fluoromethyl-2-nitroanilino, 4-trifluoromethyl-3-nitro-anilino, 4- cyano-2-nitroanilino, 2-naphthylamino, 4-hydroxysulfonyl-1-naphtylamino, quinolylamino, nitroquinolylamino and the like.
• pNA p-nitroanilino
• 2-carboxy-4-nitroanilino and 3-carboxy-4-nitroanilino
• the preferred group R according to the invention is a chromogenic group, namely, on the one hand, pNA and, on the other hand, analogous groups, where the phenyl nucleus of pNA is substituted in position 2 or 3, and corresponding to the formula
• the addition salts according to the invention are essentially acid addition salts obtained by reaction of a compound of formula I with a mineral or organic acid.
• a 1 represents D-THC, D-TZC, D-ATC, D-AZC, L-THC, L-TZC, L-ATC or L-AZC,
• a 2 represents L-Pro, L-3Hyp or L-4Hyp, and A 3 represents L-Arg or L-Lys;
• an amino acid residue A 1 representing L-TZC, L-ATC and better still L-THC.
• T represents OH, F, Cl or Br.
• the reaction medium will comprise an excess base acting as co-solvent and as proton acceptor, such as Et 3 N or DIEA.
• a coupling agent will also be incorporated into said reaction medium, in particular Bop or HOBT, in particular when T is OH.
• HOBT a coupling agent, it will be advantageous to associate with said agent an appropriate amount of DCCI.
• the tripeptide compounds of formula I and their addition salts constitute specific substrates for Protein C.
• the method for determining Protein C which is recommended is characterized in that it is brought into contact in an aqueous liquid medium suitable such as a buffered saline, a given amount of a tripeptide of formula I or one of its addition salts (at a concentration of the order of 10 mg / ml) and a sample to be tested (possibly diluted) likely to contain Protein C, for at least 0.5 h at a temperature between RT and 40 ° C, especially 37 ° C.
• kit, kit or assay kit intended for the determination of Protein C containing a tripeptide of formula I or one of its addition salts, and if necessary, a standard sample of Protein C (of human or bovine origin) and buffered dilution media.
• the resulting solution is then successively extracted three times with small amounts of 0.5 M NaHCO 3 , three times with a KHSO 4 solution at 50 g / 1 and then several times with H 2 O semi-saturated with NaCl.
• the organic phase is then dried over anhydrous sodium sulfate. After filtration (elimination of Na 2 SO 4 ), the solvent is evaporated and the evaporation residue is recrystallized from the AcOEt / MeOMe (3/7) v / v mixture. 3.5 g of the expected product are obtained, in the form of a white powder. Mp 128-130 ° C.
• reaction at RT for 1.5 h of a reaction mixture comprising (i) 800 mg (1.3 mmol) of HL-Pro-L-Arg-pNA , 2H-TFA, (ii) 190 mg (1.3 mmol) of H-THC-OH, (iii) 1 ml of DIEA and (iv) 5.75 mg (1.3 mmol) of Bop, in DMF under agitation.
• the reaction mixture is then evaporated in vacuo and then precipitated in EtOEt.
• the white precipitate obtained is taken up in a minimum quantity of a solvent system CHCl 3 / MeOH / AcOH (5/3/1) v / v and chromatography on silica gel using the same solvent system. The homogeneous fractions are recovered. These are collected and evaporated. 410 g (yield: 54%) of the expected product are obtained.
• Example 1 The product of Example 1 is prepared by replacing the chromatography on silica gel provided for in stage le with an HPLC (HYPERSIL R C 18 column with a particle size of 3 micrometers). A purer product is obtained than that obtained in preparation I.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Microbiology (AREA)
• Immunology (AREA)
• Biotechnology (AREA)
• Analytical Chemistry (AREA)
• Physics & Mathematics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Neurosurgery (AREA)
• Hematology (AREA)
• Medicinal Chemistry (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=9393865

Family Applications (1)

Country Status (6)

Citations (4)

• 1990
  • 1990-01-18 JP JP2502550A patent/JP2769243B2/ja not_active Expired - Lifetime
  • 1990-02-19 FR FR9001966A patent/FR2658520A1/fr active Granted
  • 1990-12-31 US US07/768,617 patent/US5362851A/en not_active Expired - Lifetime
  • 1990-12-31 EP EP91902722A patent/EP0469102B1/fr not_active Expired - Lifetime
  • 1990-12-31 WO PCT/FR1990/000973 patent/WO1991012268A1/fr not_active Ceased
  • 1990-12-31 DE DE69017446T patent/DE69017446T2/de not_active Expired - Lifetime

Patent Citations (4)

Also Published As

Similar Documents

Legal Events